Respiratory Syncytial Virus, Subgroup A, Stabilized Prefusion F Protein 847A, Respiratory Syncytial Virus, Subgroup B, Stabilized Prefusion F Protein 847B

5 trials 3 recruiting JAnti-infectives

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

0 Completed trials

6 Sponsors

6 Countries

Phase III

Phase II/III

Phase IV

Phase III: 2 Phase II/III: 1 Phase IV: 2

Indications tested

Bronchiolitis 1 Rheumatoid arthritis 1 Polymyalgia rheumatica 1 Polyarthritis 1 Giant cell arteritis 1 Systemic lupus erythematosus 1

Sponsors using this IMP

Centre Hospitalier Annecy Genevois 1 Centre hospitalier universitaire de Liege 1 Fondazione Penta Ets 1 Gentofte Hospital 1 Pfizer Inc. 1 Region Skane 1

All trials

5 total

Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on… Pending

2024-518191-31-00 Phase IV 1 country Region Skane
Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial (PIPELINE-RSV) Pending

2025-522194-11-00 Phase III 2 countries Fondazione Penta Ets
PIPELINE-RSV-France Recruiting

2025-521755-23-00 Phase III 1 country Centre Hospitalier Annecy Genevois
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years o… Recruiting

2024-516600-42-00 Phase IV 2 countries Gentofte Hospital; Pfizer Inc.
A Phase II randomized trial of RSV vaccination in allogeneic hematopoietic stem cell transplant recipients (RSV-Allo study) Recruiting

2024-513290-53-00 Phase II/III 1 country Centre hospitalier universitaire de Liege

Showing 1–5 of 5 trials

← All drugs A–Z